Literature DB >> 7167137

Acute and chronic diuretic-induced alterations in urinary sodium and calcium excretion in the conscious rat.

R C Hanson, J B White, A W Gomoll.   

Abstract

The acute and chronic (5-day) effects of three low-ceiling diuretics (hydrochlorothiazide, indapamide or xipamide) and two high-ceiling diuretics (furosemide or muzolimine) on urinary volume and electrolyte excretion were examined in the saline-loaded conscious rat. The three low-ceiling agents produced qualitatively similar alterations in both acute and chronic volume and electrolyte excretion patterns. Each of these agents produced an acute disassociation between urinary sodium and calcium excretion and hypocalciuria after chronic administration. It is suggested that indapamide and xipamide, like hydrochlorothiazide, inhibit sodium but not calcium reabsorption in the distal nephron. Acute as well as chronic treatment with either furosemide or muzolimine produced dose-dependent increases in urinary volume and electrolyte excretion. A generally parallel response was observed on sodium and calcium excretion with these agents. It is suggested that muzolimine, like furosemide, inhibits both sodium and calcium reabsorption in the ascending limb of Henle's loop.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7167137

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  2 in total

1.  NHE3 in the thick ascending limb is required for sustained but not acute furosemide-induced urinary acidification.

Authors:  Jianxiang Xue; Linto Thomas; Jessica A Dominguez Rieg; Robert A Fenton; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2022-05-30

2.  The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.

Authors:  Lakshmi Kantham; Steven J Quinn; Ogo I Egbuna; Khanjan Baxi; Robert Butters; Jian L Pang; Martin R Pollak; David Goltzman; Edward M Brown
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10       Impact factor: 4.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.